Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fallat, M. E.
Right arrow Articles by MacLaughlin, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fallat, M. E.
Right arrow Articles by MacLaughlin, D. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 11, No. 10, pp. 2165-2169, 1996
© 1996 European Society of Human Reproduction and Embryology

research-article

Andrology: The presence of Müllerian inhibiting substance in human seminal plasma

Mary E. Fallat1,4, Yong Siow1, Arnold M. Belker1,2, Julia K. Boyd1, Sheryl Yoffe2 and David T. MacLaughlin3

1Department of Surgery, University of Louisville Louisville, KY 40292 2Jewish Hospital Louisville, KY 40292 3Department of Pediatric Surgery, Massachusetts General Hospital Boston, MA 02114, USA

Correspondence: 4To whom correspondence should be addressed at: Kosair Children's Hospital, PO Box 35070, Louisville, KY 40232–5070, USA

Müllerian inhibiting substance (MIS), produced by testicu-Iar Sertoli cells, is present in adult male serum. The first aim of this study was to determine if MIS is present in seminal plasma. Using an enzyme-linked immunosorbent assay (ELISA), we measured MIS concentrations in seminal plasma from 23 donors exhibiting normal (WHO criteria) sperm qualities, and 169 patients with subnormal sperm parameters. The second aim of this study was to examine a potential relationship between MIS and sperm motility. MIS concentrations in seminal plasma ranged from 0.5 to 3.6 ng/ml in donors and from 0.5 to 17.8 ng/ml in patients. Motility index (MI, mean ± SEM) for all patient samples was lower compared with donors (113.3 ± 3.2 and 1983 ± 13.5, P < 0.00001), while mean MIS concentration (± SEM) was higher (4.2 ± 03 and 1.4 ± 0.2, P < 0.0003). When the patients were stratified into Groups I (motility < 50%, n = 42) and D (motility >50%, n = 127), the MI (mean ± SEM) values were 623 ± 3.8 and 130.2 ± 2.7 respectively (P < 0.0001 for both compared with donors) and mean MIS concentrations (± SEM) were 5.4 ± 0.6 and 3.9 ± 03, respectively (P < 0.0001 and P < 0.001 compared with donors). The inverse relationship between MIS concentration in seminal plasma and motility index suggests that MIS may have a function in modulating motility.

Key words: MIS/seminal plasma/sperm motility


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J AndrolHome page
X. Wu, S. Wan, S. Pujar, M. E. Haskins, D. H. Schlafer, M. M. Lee, and V. N. Meyers-Wallen
A Single Base Pair Mutation Encoding a Premature Stop Codon in the MIS Type II Receptor Is Responsible for Canine Persistent Mullerian Duct Syndrome
J Androl, January 1, 2009; 30(1): 46 - 56.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A.A. Sinisi, D. Esposito, L. Maione, M.C. Quinto, D. Visconti, A. De Bellis, A. Bellastella, G. Conzo, and G. Bellastella
Seminal anti-Mullerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism
Hum. Reprod., May 1, 2008; 23(5): 1029 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Fujisawa, T. Yamasaki, H. Okada, and S. Kamidono
The significance of anti-Mullerian hormone concentration in seminal plasma for spermatogenesis
Hum. Reprod., April 1, 2002; 17(4): 968 - 970.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Teixeira, S. Maheswaran, and P. K. Donahoe
Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications
Endocr. Rev., October 1, 2001; 22(5): 657 - 674.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W.-Q. Long, V. Ranchin, P. Pautier, C. Belville, P. Denizot, H. Cailla, C. Lhommé, J.-Y. Picard, J.-M. Bidart, and R. Rey
Detection of Minimal Levels of Serum Anti-Mullerian Hormone during Follow-Up of Patients with Ovarian Granulosa Cell Tumor by Means of a Highly Sensitive Enzyme-Linked Immunosorbent Assay
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 540 - 544.
[Abstract] [Full Text]

Home page
 Hum ReprodHome page
P. Fenichel, R. Rey, S. Poggioli, M. Donzeau, D. Chevallier, and G. Pointis
Anti-Mullerian hormone as a seminal marker for spermatogenesis in non-obstructive azoospermia
Hum. Reprod., August 1, 1999; 14(8): 2020 - 2024.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Racine, R. Rey, M. G. Forest, F. Louis, A. Ferre, I. Huhtaniemi, N. Josso, and N. di Clemente
Receptors for anti-Mullerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation
PNAS, January 20, 1998; 95(2): 594 - 599.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.